Head to Head Comparison: Cellect Biotechnology (APOP) & Its Peers

Cellect Biotechnology (NASDAQ: APOP) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare Cellect Biotechnology to similar businesses based on the strength of its analyst recommendations, valuation, dividends, institutional ownership, risk, earnings and profitability.


How to Become a New Pot Stock Millionaire

This table compares Cellect Biotechnology and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellect Biotechnology N/A -153.95% -92.92%
Cellect Biotechnology Competitors -62.26% -47.35% -18.28%

Analyst Recommendations

This is a summary of recent ratings for Cellect Biotechnology and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellect Biotechnology 0 0 1 0 3.00
Cellect Biotechnology Competitors 491 1883 3745 115 2.56

Cellect Biotechnology currently has a consensus price target of $14.00, suggesting a potential upside of 103.49%. As a group, “Surgical & medical instruments” companies have a potential upside of 9.42%. Given Cellect Biotechnology’s stronger consensus rating and higher possible upside, analysts plainly believe Cellect Biotechnology is more favorable than its rivals.

Volatility and Risk

Cellect Biotechnology has a beta of 4.59, meaning that its stock price is 359% more volatile than the S&P 500. Comparatively, Cellect Biotechnology’s rivals have a beta of 0.80, meaning that their average stock price is 20% less volatile than the S&P 500.

Earnings & Valuation

This table compares Cellect Biotechnology and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cellect Biotechnology N/A -$8.14 million -4.71
Cellect Biotechnology Competitors $1.54 billion $111.80 million -144.37

Cellect Biotechnology’s rivals have higher revenue and earnings than Cellect Biotechnology. Cellect Biotechnology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

0.6% of Cellect Biotechnology shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.4% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


Cellect Biotechnology rivals beat Cellect Biotechnology on 7 of the 13 factors compared.

About Cellect Biotechnology

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply